|By PR Newswire||
|September 4, 2014 09:20 AM EDT||
NEW YORK, September 4, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6210-100free.
Gilead Sciences, Inc. Research Reports
Gilead Sciences, Inc. posted on the Event Details section of its official website that the Company will participate in the upcoming 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on September 5, 2014 through September 9, 2014 in Washington, DC. The full research reports on Gilead are available to download free of charge at:
Pfizer Inc. Research Reports
On August 28, 2014, Pfizer Inc. (Pfizer) and Protalix BioTherapeutics, Inc. jointly announced that the U.S. Food and Drug Administration (FDA) has approved ELELYSO™ (taliglucerase alfa) for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease. The Company informed that the safety and efficacy of ELELYSO were assessed in fourteen pediatric patients with Type 1 Gaucher disease in two clinical trials. Rory O'Connor, Senior Vice President, Global Medical Affairs, Global Innovative Pharma Business, Pfizer, said, "The approval of ELELYSO to treat pediatric patients with Type 1 Gaucher disease provides physicians another treatment option for this rare and potentially debilitating disease." The full research reports on Pfizer are available to download free of charge at:
AbbVie Inc. Research Reports
On August 29, 2014, AbbVie Inc.'s (AbbVie) stock declined 0.58% to end the trading session at $55.28, underperforming the broader market index- S&P 500 that gained 0.33% over the same trading session. AbbVie's stock opened the session at $55.75 and fluctuated between $55.24 and $55.80. Over the past twelve months, AbbVie stock has returned 29.73%, outperforming the S&P 500 that returned 22.68% over the same period of time. The full research reports on AbbVie are available to download free of charge at:
Express Scripts Holding Company Research Reports
On August 29, 2014, shares in Express Scripts Holding Company (Express Scripts) moved up 0.15% to close the trading session at $73.93, after declining 1.20% in previous trading session. Shares in Express Scripts opened the session at $74.49 and oscillated in the range of $73.75 - $74.49. Express Scripts' stock has a 52-week high of $79.37 and a 52-week low of $59.20. Over the past one month, the stock has strengthened 4.70% compared to Nasdaq Composite that gained 2.63% over the same period of time. The full research reports on Express Scripts are available to download free of charge at:
Thermo Fisher Scientific Inc. Research Reports
On August 25, 2014, Thermo Fisher Scientific Inc. (Thermo Fisher) reported that the European Union's Marie Curie European Industrial Doctorate program provided €1.2 million grant to four early-stage researchers from Asia, Australia and Europe to study the environmental effects of one of the most common types of flame retardants. The Company informed that the four-year grant, titled "Elucidating Sources and Pathways of Environmental Contamination with Brominated Persistent Organic Chemicals Using Advanced Instrumental Tools (ELUTE)," will allow researchers to pursue individual projects in the laboratory of Stuart Harrad, MSc, Ph.D. at the University of Birmingham, UK, and the Thermo Fisher Scientific Persistent Organic Pollutants (POPs) Center of Excellence in Bremen, Germany. Kyle D'Silva, Product Manager, Thermo Fisher, and Director of research for ELUTE, said, "We're very pleased to be a partner in this important environmental research. It aligns perfectly with our corporate mission to enable our customers to make the world healthier, cleaner and safer." The full research reports on Thermo Fisher are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Dec. 9, 2016 03:45 PM EST Reads: 560
Dec. 9, 2016 03:30 PM EST Reads: 1,224
Dec. 9, 2016 03:15 PM EST Reads: 975
Dec. 9, 2016 03:15 PM EST Reads: 852
Dec. 9, 2016 03:00 PM EST Reads: 2,007
Dec. 9, 2016 03:00 PM EST Reads: 351
Dec. 9, 2016 02:45 PM EST Reads: 1,034
Dec. 9, 2016 02:45 PM EST Reads: 622
Dec. 9, 2016 02:42 PM EST Reads: 192
Dec. 9, 2016 02:30 PM EST Reads: 1,258
Dec. 9, 2016 02:30 PM EST Reads: 788
Dec. 9, 2016 02:15 PM EST Reads: 377
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Phil Hombledal, Solution Architect at CollabNet, discussed how customers are able to achieve a level of transparency that e...
Dec. 9, 2016 02:15 PM EST Reads: 1,290
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
Dec. 9, 2016 02:15 PM EST Reads: 1,776
Dec. 9, 2016 02:15 PM EST Reads: 813